Assistant Director – I-Motion Medical Staff Manager: Dr Marina Colella, MD, PhD
Assistant Director – I-Motion Non-medical Staff Manager: Saadane Kirouani

The adult clinical trials unit is dedicated to clinical research in adults focusing on therapeutic trials, natural histories, medical devices and observational studies. 

The I-Motion Adults platform is located in the Babinski building on the site of the Pitié-Salpêtrière University Hospital and works in close collaboration with the Service of Neuro-Myology headed by Prof. Bertrand Fontaine and with the different poles of the Hospital and research laboratories from the Institute of Myology. 

The team consists of a clinical studies doctor, project managers, clinical research associates and a quality engineer. 

In 2024, 44 trials in adults with 33 new inclusions and 308 patients under follow-up, including 4 phase I, 12 phase II and 8 phase III trials. Access the complete list of registries, databases and clinical trials currently running at the Institute.

Team members

Dr Marina Colella, MD, PhD, Paediatrician, Assistant Director – I-Motion Medical Staff Manager
Saadane Kirouani, Assistant Director – I-Motion Non-medical Staff Manager

Medical and paramedical staff
Dr. Amani Zaayter, MD, Pediatric Neurologist
Dr. Amal Oulhissane-Omar, MD, Pediatrician
Dr. Marc Abi Aoun, MD, Neurologist

Non medical staff
Maïa Narimanidze-Rambaud, Project Manager, Clinical Research Associates (CRA) Coordinator
Erwan Gasnier, PhD, Project Manager
Smail Ait Mohand, Project Manager
Nassima Ait-Tahar, Project Manager

Fanny Moraux, Quality Engineer

Dina Ferhat, Clinical Research Associate (CRA)
Sonia Bozourine, Clinical Research Associate (CRA)
Asma Balloumi, Clinical Research Associate (CRA)
Thiziri Iassamen, Clinical Research Associate (CRA)
Bahareh Ghanizadeh, Clinical Research Associate (CRA)
Ouardia Berkouk, Trainee Clinical Research Associate (Trainee CRA)

Stéphanie Raymond, Multi-skilled Manager

Last publications

• Quantitative brainstem and spinal MRI in amyotrophic lateral sclerosis: implications for predicting noninvasive ventilation needs. Khamaysa M, Lefort M, Pélégrini-Issac M, Lackmy-Vallée A, Mendili MME, Preuilh A, Devos D, Bruneteau G, Salachas F, Lenglet T, Amador MM, Le Forestier N, Hesters A, Gonzalez J, Rolland AS, Desnuelle C, Chupin M, Querin G, Georges M, Morelot-Panzini C, Marchand-Pauvert V, Pradat PF; Pulse Study Group. J Neurol. 2024 Mar;271(3):1235-1246. doi: 10.1007/s00415-023-12045-x. Epub 2023 Nov 1. PMID: 37910250
• Gene therapy for primary myopathies: literature review and prospects. Querin G, Colella M. Arch Pediatr. 2023 Nov;30(8S1):8S18-8S23. doi: 10.1016/S0929-693X(23)00223-3. PMID: 38043978 
• Anoctamin-5 related muscle disease: clinical and genetic findings in a large European cohort. de Bruyn A, Montagnese F, Holm-Yildiz S, Scharff Poulsen N, Stojkovic T, Behin A, Palmio J, Jokela M, De Bleecker JL, de Visser M, van der Kooi AJ, Ten Dam L, Domínguez González C, Maggi L, Gallone A, Kostera-Pruszczyk A, Macias A, Łusakowska A, Nedkova V, Olive M, Álvarez-Velasco R, Wanschitz J, Paradas C, Mavillard F, Querin G, Fernández-Eulate G, Quinlivan R, Walter MC, Depuydt CE, Udd B, Vissing J, Schoser B, Claeys KG. Brain. 2023 Sep 1;146(9):3800-3815. doi: 10.1093/brain/awad088. PMID: 36913258
• Phenotype Presentation and Molecular Diagnostic Yield in Non-5q Spinal Muscular Atrophy. Fernández-Eulate G, Theuriet J, Record CJ, Querin G, Masingue M, Leonard-Louis S, Behin A, Le Forestier N, Pegat A, Michaud M, Chanson JB, Nadaj-Pakleza A, Tard C, Bedat-Millet AL, Sole G, Spinazzi M, Salort-Campana E, Echaniz-Laguna A, Poinsignon V, Latour P, Reilly MM, Bouhour F, Stojkovic T. Neurol Genet. 2023 Jul 17;9(4):e200087. doi: 10.1212/NXG.0000000000200087. eCollection 2023 Aug. PMID: 37470033 
• Comparison of spinal magnetic resonance imaging and classical clinical factors in predicting motor capacity in amyotrophic lateral sclerosis. Khamaysa M, Lefort M, Pélégrini-Issac M, Lackmy-Vallée A, Preuilh A, Devos D, Rolland AS, Desnuelle C, Chupin M, Marchand-Pauvert V, Querin G, Pradat PF; Pulse study group. J Neurol. 2023 Aug;270(8):3885-3895. doi: 10.1007/s00415-023-11727-w. Epub 2023 Apr 27. PMID: 37103756
• Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study. Bril V, Drużdż A, Grosskreutz J, Habib AA, Mantegazza R, Sacconi S, Utsugisawa K, Vissing J, Vu T, Boehnlein M, Bozorg A, Gayfieva M, Greve B, Woltering F, Kaminski HJ; MG0003 study team. Lancet Neurol. 2023 May;22(5):383-394. doi: 10.1016/S1474-4422(23)00077-7. PMID: 37059507